Geron GERN
NASDAQ GERN
$1.38 -0.02 (-1.78%)
As of: Sep 10, 2026 · 3:59 PM EDT

Geron (GERN) Current Deferred Revenue (2010 - 2015)

Geron's (GERN) quarterly Current Deferred Revenue came in at $35.0 million in Q2 2015, little changed quarter-over-quarter from $35.0 million in Q1 2015.

Analysis

Geron (GERN) Current Deferred Revenue (2010 - 2015) Analysis & Trends

Geron has disclosed Current Deferred Revenue across 3 years of filings, most recently posting $35.0 million for Q2 2015.

  • In Q2 2015, Current Deferred Revenue changed N/A year-over-year to $35.0 million; the TTM figure through Jun 2015 stood at $35.0 million (changed N/A YoY), while the FY2014 annual figure was $35.0 million, changed N/A from the prior year.
  • Current Deferred Revenue came in at $35.0 million for Q2 2015 at Geron, roughly flat from $35.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $35.0 million in Q4 2014 to a low of $35.0 million in Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Geron 914.60 Mn 613.75 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 35.00 Mn
Mar 31, 2015 35.00 Mn
Dec 31, 2014 35.00 Mn
Dec 31, 2010 350,000.00